| Literature DB >> 24281212 |
Gabriella Fabbrocini1, Maria Triassi, Maria Chiara Mauriello, Guglielma Torre, Maria Carmela Annunziata, Valerio De Vita, Francesco Pastore, Vincenza D'Arco, Giuseppe Monfrecola.
Abstract
The incidence rate of melanoma and non-melanoma skin cancer entities is dramatically increasing worldwide. Exposure to UVB radiation is known to induce basal and squamous cell skin cancer in a dose-dependent way and the depletion of stratospheric ozone has implications for increases in biologically damaging solar UVB radiation reaching the earth's surface. In humans, arsenic is known to cause cancer of the skin, as well as cancer of the lung, bladder, liver, and kidney. Exposure to high levels of arsenic in drinking water has been recognized in some regions of the world. SCC and BCC (squamous and basal cell carcinoma) have been reported to be associated with ingestion of arsenic alone or in combination with other risk factors. The impact of changes in ambient temperature will influence people's behavior and the time they spend outdoors. Higher temperatures accompanying climate change may lead, among many other effects, to increasing incidence of skin cancer.Entities:
Year: 2010 PMID: 24281212 PMCID: PMC3840456 DOI: 10.3390/cancers2041980
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Ozone Production. Ozone is created by oxygen molecules and energetic UV radiation [9].
Figure 2UVB DNA damage. UVB radiation may lead to direct DNA damage, inducing the development of thymine dimers, whereby adjacent thymine bases bond with each other instead of across the DNA backbone ladder. This thymine dimer makes a bulge, and the distorted DNA molecule does not function properly [10].
Figure 3Cellular targets of arsenic trioxide action, with multiple pathways in malignant cells resulting in apoptosis or in the promotion of differentiation. Potential molecular targets for arsenic trioxide and arsenite are shown in gray. Abbreviations: AP1, activator protein-1; Apaf, apoptotic protease-activating factor; CK2, casein kinase; Co-A, coenzyme A; DAXX, death-associated protein; ER, estrogen receptor; FADH, flavin adenine dinucleotide; PARP, poly-(ADP-ribose)-polymerase; PML, promyelocytic leukemia. Modified from Miller et al. (32) with permission from the American Association for Cancer Research.